Healthcare [ 5/11 ] | Biotechnology [ 53/112 ]
US | AMEX | Stock
Reported Date | EPSChange YoY | EstimateSurprise |
---|---|---|
May 11, 23 | -0.40
Decreased by
-33.33%
|
-0.32
Decreased by
-78.13%
|
Mar 16, 23 | -0.29
Decreased by
-26.09%
|
-0.28
Decreased by
-12.76%
|
Nov 9, 22 | -0.24
Decreased by
-9.09%
|
-0.28
Increased by
+51.02%
|
Aug 11, 22 | -0.26
Decreased by
-4.00%
|
-0.23
Decreased by
-56.71%
|
May 12, 22 | -0.30
Decreased by
-11.11%
|
-0.21
Decreased by
-204.08%
|
Mar 17, 22 | -0.23
Increased by
+36.11%
|
-0.28
Increased by
+63.78%
|
Nov 10, 21 | -0.22
Increased by
+29.03%
|
-0.26
Increased by
+59.17%
|
Aug 12, 21 | -0.25
Increased by
+3.85%
|
-0.26
Increased by
+14.79%
|
Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
---|---|---|---|
Mar 31, 23 | 0.00
Decreased by
N/A%
|
-17.63 M
Decreased by
-101.00%
|
Decreased by
N/A%
Decreased by
N/A%
|
Dec 31, 22 | 0.00
Decreased by
N/A%
|
-10.30 M
Decreased by
-70.35%
|
Decreased by
N/A%
Decreased by
N/A%
|
Sep 30, 22 | 0.00
Decreased by
N/A%
|
-8.61 M
Decreased by
-58.79%
|
Decreased by
N/A%
Decreased by
N/A%
|
Jun 30, 22 | 0.00
Decreased by
N/A%
|
-9.21 M
Decreased by
-48.69%
|
Decreased by
N/A%
Decreased by
N/A%
|
Mar 31, 22 | 0.00
Decreased by
N/A%
|
-8.77 M
Decreased by
-59.65%
|
Decreased by
N/A%
Decreased by
N/A%
|
Dec 31, 21 | 0.00
Decreased by
N/A%
|
-6.05 M
Increased by
+8.71%
|
Decreased by
N/A%
Decreased by
N/A%
|
Sep 30, 21 | 0.00
Decreased by
N/A%
|
-5.42 M
Increased by
+6.07%
|
Decreased by
N/A%
Decreased by
N/A%
|
Jun 30, 21 | 0.00
Decreased by
-100.00%
|
-6.19 M
Decreased by
-31.51%
|
Decreased by
N/A%
Decreased by
N/A%
|
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.